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ABSTRACT OF THE THESIS 
Associations Between Prenatal Selective Serotonin Reuptake Inhibitor Exposure, Depression and 
Brain Morphology in Middle Childhood 
by 
Allison Moreau 
Master of Arts in Psychological and Brain Sciences 
Washington University in St. Louis, 2019 
 
 
Objective: Selective Serotonin Reuptake Inhibitors (SSRIs) are one of the most widely used 
prescribed medicine by pregnant women. A mixed literature suggests that prenatal SSRI 
exposure may increase depression risk among offspring. 
Method: Using data from children (n=11,076) who completed the baseline session of the 
Adolescent Brain and Cognitive Development (ABCD) study, we examined whether prenatal 
exposure to SSRIs is associated with child depression and variability in depression-related brain 
structures (i.e., hippocampus, amygdala, nucleus accumbens, caudate, putamen; rostral anterior 
cingulate; rostral and caudal middle frontal, superior frontal, and lateral and medical 
orbitofrontal cortices). Analyses were cross-sectional and included the following covariates: sex, 
race, ethnicity, age, birthweight, household income, maternal education, whether pregnancy was 
planned, gestational age when mother aware of pregnancy, prenatal exposure to prenatal 
vitamins, tobacco, marijuana, and alcohol. Lifetime maternal depression was included when not 







Results: Prenatal SSRI exposure and maternal depression were each independently associated 
with depressive symptoms among children. No gray matter-based imaging metrics were 
associated with SSRI exposure following correction for multiple testing. SSRI exposure was 
nominally associated with reduced caudate, amygdala, and hippocampal volumes (all ps <0.045). 
Conclusion: We find evidence that prenatal SSRI exposure is associated with elevated depressive 
symptoms among children, even after accounting for lifetime maternal depression. Imaging 
derived metrics of gray matter (i.e., subcortical volume, cortical thickness of brain regions 
associated with depression) may not play a mechanistic role in prenatal SSRI exposure-related 





Chapter 1: Introduction 
Over the past 2 decades, national survey data indicate that the use of antidepressant 
medication increased by 594% in the United States. Between 2011-2014, 10.7% of the United 
States population reported using an antidepressant medication in the past 30 days, compared to 
1.8% of the population between 1988-1994 (Center for Health Statistics, 2017). As women are at 
greater risk than men for depression, and the time period corresponding to reproductive years is 
associated with the greatest risk, it is perhaps unsurprising that among the 50% of pregnant 
women taking prescribed medication Selective Serotonin Reuptake Inhibitors (SSRIs) are among 
the most commonly used classes of medication. In 2008, over 7% of pregnant women in the US 
took them at some point during pregnancy (Mitchell et al., 2011). However, the impact of 
prenatal SSRI exposure on children is poorly understood. Prenatal SSRI exposure has been 
associated with a host of adverse physical outcomes (e.g., diminished fetal growth, hypertension) 
(Yonkers, Blackwell, Glover, & Forray, 2014), with mixed evidence that it may (e.g., 
Brandlistuen et al., 2015; Hanley, Brain, & Oberlander, 2015; Hermansen, Røysamb, Augusti, & 
Melinder, 2016; Liu et al., 2017; Lupattelli et al., 2018; Malm et al., 2016) or may not (e.g.,  
Grzeskowiak et al., 2016; Misri et al., 2006; Nulman et al., 2012, 2015, 1997) predispose 
offspring to depression, even when considering maternal depression. Given that SSRIs represent 
one of the most commonly used forms of prescribed medication among pregnant women, and a 
mixed literature suggesting that prenatal SSRI exposure may be associated with depression risk 
among offspring, it is critical to further investigate this relationship as well as the neural 





Initial studies (n=2) comparing offspring (ages 1.3-5) born to depressed mothers who 
used SSRIs during pregnancy (Ns=22, 55) to nondepressed mothers who did not (Ns=14, 84) 
found no difference in depression and related behavior among offspring (Misri et al., 2006; 
Nulman et al., 1997); (reviewed in Gentile & Galbally, 2011). These initial null findings have 
been followed by mixed data from humans and non-human animal models that SSRI exposure 
may or may not increase risk for depression and related behavior among offspring. In rodents, 
perinatal SSRI exposure (equivalent to the third trimester in humans) is associated with elevated 
depressive-like behavior in later adulthood (Ansorge et al., 2004). Suggestive of potential 
conservation across species, some recent human studies (Ns ranging from 28-44 exposed 
children; child ages ranging from 3-15) have reported that children exposed to SSRIs prenatally 
are at increased risk for depression and internalizing psychopathology (Hanley et al., 2015; 
Hermansen et al., 2016; Liu et al., 2017; Lupattelli et al., 2018; Malm et al., 2016).  Notably, 
some of these studies controlled for maternal mood during pregnancy and childhood (Hanley et 
al., 2015) or included an unexposed depressed control group (Hermansen et al., 2016) suggesting 
that the association between SSRI exposure and offspring depression may be independent of 
depression exposure during pregnancy.  Such speculation is further supported by a sibling-
matched control study that found that offspring who were exposed to SSRIs displayed greater 
anxiety symptoms at 3 years, but not 18 months, than their unexposed siblings (Brandlistuen et 
al., 2015). As this study matched mothers, it provides the most compelling evidence of a 
potential impact of prenatal SSRI exposure on internalizing symptoms in humans. At the same 
time, another sibling-matched control study found no differences in internalizing behavior 
between exposed and unexposed siblings that ranged in age from 3-7 years old (Nulman et al., 





found no evidence that prenatal SSRI exposure (Ns: 62-210) is associated with depression by 
ages 3-7 (Grzeskowiak et al., 2016; Nulman et al., 2012). Collectively, there is mixed evidence 
suggesting that SSRI exposure may or may not be independently associated with depression risk 
among offspring.  
 In contrast to this sizable body of literature looking at prenatal SSRI exposure and 
offspring depression, there is a limited literature examining associations between prenatal SSRI 
exposure and offspring brain structure. This is unfortunate because non-human animal models 
suggest that SSRIs may contribute to risk for depression in offspring by altering brain 
development (e.g., Gingrich et al., 2017). Indeed, we are only aware of two such human studies, 
which were conducted in neonates and produced conflicting findings (Jha et al., 2016; Lugo-
Candelas et al., 2018). Jha and colleagues (2016) found no differences in global or regional brain 
volume between SSRI-exposed and unexposed (healthy control or untreated prenatal maternal 
depression) neonates (total N=204), while Lugo-Candelas and colleagues (2018) found increased 
gray matter volume in the right amygdala and insula and left superior frontal and occipital gyri 
for SSRI-exposed infants compared to healthy controls and infants exposed to untreated maternal 
depression (total N=98).  
 In the present study, we examined whether self-reported maternal use of SSRIs is 
associated with brain structure (volume and cortical thickness) and depressive symptoms among 
the 11,875 children (average age 10) who participated in the baseline Adolescent Brain 
Cognitive Development (ABCD) study. Regions of interest that have been previously associated 
with depression were selected for a priori analyses: cortical regions of rostral anterior cingulate, 





cortex and the subcortical regions hippocampus, amygdala, nucleus accumbens, caudate and 
putamen (Schmaal et al., 2017, 2016; Wise, Cleare, Herane, Young, & Arnone, 2014).  
We hypothesize that SSRI exposure will be associated with reduced volume and cortical 
thickness across ROIs. Given that participants have yet to enter peak periods of risk for Major 
Depressive Disorder, adolescence, (Kessler, Avenevoli, & Ries Merikangas, 2001), we 






Chapter 2: Methods 
 
2.1 Participants 
Data came from children (n=11,875; Mage = 9.9±0.6 years; 47.85% girls; 74.13% White) born 
between 2005 and 2009 to 9,987 mothers through 10,801 pregnancies who completed the 
baseline session of the ongoing longitudinal Adolescent Brain Cognitive Development (ABCD) 
study (data release 2.0.1; https://abcdstudy.org/). The study includes a family-based design in 
which twin (n=2,108), triplet (n=30), non-twin siblings (n=1,589), and singletons (n=8,148) were 
recruited. All parents provided written informed consent, and all children provided verbal assent 
to a research protocol approved by the institutional review board at each data collection site 
(n=22)1 throughout the United States (https://abcdstudy.org/sites/abcd-sites.html). For our 
analyses, participants who had quality-controlled non-missing structural MRI data were included 
(N=11,076; aged 9-10 years old; 48% female; 74.8% of European ancestry; 20.8% of African 
ancestry; 6.1% of Asian ancestry; 10.5% other ancestry; Table 1). A total of 299 children 
(2.70%) were exposed to SSRIs prenatally. 
2.2 Measures 
2.2.1 Prenatal Medication Exposure  
A parent or caregiver (91.5% mothers) retrospectively reported medications used by the mother 
during pregnancy, before and after maternal knowledge of pregnancy. We coded medication use 
according to categories (Table 2), including selective serotonin reuptake inhibitors (SSRIs).  
 
1 Cornell University was an original collection site that collected data from 34 participants, 
before being moved to Yale University. ABCD documentation reports 21 data collection sites 
and does not list Cornell; our analyses nested data based on 22 data collection sites, including the 





2.2.2 Child Structural MRI  
ABCD study imaging acquisition protocol and parameters as well as image processing and 
analysis methods are described in detail in Casey et al. (2018) and Hagler et al. (2019), 
respectively. Briefly, 1 mm isotropic T1-weighted structural images were acquired from 
magnetization-prepared rapid acquisition gradient echo scans on 3 T (Siemens, Phillips and GE) 
MRI scanners using either a 32-channel head or 64-channel head-and-neck coil. Scan protocols 
were carefully harmonized across the three MRI vendor platforms to reduce scanner-related 
variability. Head motion is a significant concern for pediatric imaging, so real-time motion 
detection and correction was implemented (prospective motion correction (PROMO; (White et 
al., 2010)) on the GE and Volumetric Navigators (vNav; (Tisdall et al., 2016)) on the Siemens 
platforms). MRI data was processed with the Multi-Modal Processing Stream software package 
that includes FreeSurfer 5.3 (Dale, Fischl, & Sereno, 1999; Fischl et al., 2002; Fischl, Sereno, & 
Dale, 1999). Besides a modified intensity normalization process used by the ABCD processing 
pipeline, the standard FreeSurfer cortical and subcortical reconstruction pipeline was run to 
generate structural measures including volume and cortical thickness. Only participants whose 
structural MRI reconstructions passed QC tests (n=11,076) were included in the current analysis 
(see Hagler et al., 2019).  
Subcortical volume was investigated using the automatic subcortical segmentation in 
FreeSurfer 5.3 for the left and right hippocampi, amygdalae, nucleus accumbens, caudate and 
putamen (total n=10; Table 1). Cortical thickness was investigated using the Desikan-Killiany 
cortical parcellation map in FreeSurfer 5.3 (Desikan et al., 2006) for the average whole brain, as 





cingulate, rostral and caudal middle frontal cortex, superior frontal cortex, and lateral and medial 
orbitofrontal cortex (total regional cortical thickness n=12; Table 1).  
2.2.3 Child Depressive Symptoms   
The Child Behavior Checklist (CBCL) was completed by parents/guardians, which provides 
dimensional measures of the child depressive symptoms (Depression DSM-5 Scale; Table 1). 
The Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS-5) was administered 
to the children to determine psychiatric diagnoses, including Major Depressive Disorder, 
Persistent Depressive Disorder, and Unspecified Depressive Disorder (Table 1). 
2.2.4 Psychopathology in Mothers  
Two potential sources of information regarding maternal psychopathology were obtained in the 
ABCD Study. First, the parent, guardian or other caretaker who completed the baseline 
questionnaires was asked whether the child’s biological mother, as well as other family 
members, ever experienced a host of psychiatric disorders. Second, the caregiver also completed 
the Adult Self-Report (ASR) questionnaire, which includes scales for various psychiatric 
syndromes and disorders occurring in the past six months. For 10,131 children, the person filling 
out the questionnaires was the biological mother; thus, 10,131 children also had maternal ASR 
data. Given the topic and objective of this report, maternal depression was the only 
psychopathology investigated in both of these data sources (Table 1).  
2.2.5 Covariates 
The following variables were considered as covariates in analyses: reported child sex, race, 
ethnicity, age, birthweight, as well as household income, maternal education, lifetime maternal 
depression (when this was not the independent variable of interest), whether the pregnancy was 





exposure to prenatal vitamins, tobacco, marijuana, and alcohol (Table 1). For all imaging 
analyses, intracranial volume (ICV) was included to account for total brain volume (Table 1).   
2.3 Analyses 
As the sample contains twin and non-twin siblings, as well as 22 research sites,2 linear mixed 
effect models were used to nest data on these parameters using the lme4 (version 1.1-21) 
package in R (version 3.6.0). Our primary analyses examined whether prenatal SSRI exposure 
(i.e., before or after maternal knowledge of pregnancy, n=299) was associated with child brain 
structure (i.e., regional subcortical volumes, n=10; regional cortical thickness, n=12 + whole 
brain cortical thickness) and depressive symptoms (i.e., CBCL DSM-5 Depression Scale). 
Covariates included in these analyses included: child variables (i.e., child gender, race [i.e., 
White/not White, Black/not Black, Asian/not Asian, Native Hawaiian or Pacific Islander/not 
Native Hawaiian or Pacific Islander, Native American or Alaskan/not Native American or 
Alaskan, Other/not Other] and ethnicity (Hispanic/not Hispanic), age, birthweight), 
maternal/familial variables (i.e., household income, maternal education, lifetime maternal 
depression), and pregnancy/maternal-related variables (i.e., whether the pregnancy was planned, 
at what gestational age the mother learned of the pregnancy, and maternal use of alcohol, 
tobacco, and marijuana before and after knowledge of pregnancy as well as prenatal vitamin 
use). Analyses of brain structure also included intracranial volume (ICV) as a covariate. Multiple 
testing was adjusted for using Benjamini Hochberg False Discovery Rate (FDRBH) correction 
within each brain structure phenotype (i.e., subcortical volumes, n=10; cortical thickness, n=13). 
 
2 Cornell University was an original collection site that collected data from 34 participants, 
before being moved to Yale University. ABCD documentation reports 21 data collection sites 
and does not list Cornell; our analyses nested data based on 22 data collection sites, including the 





Following null associations between prenatal SSRI exposure and brain structure (see Results), 
we subsequently explored whether the timing of SSRI exposure contributed to differences and 
tested whether SSRI use during pregnancy before or after knowledge was associated with brain 
structure in a series of independent regressions; FDRBH was used to adjust for multiple testing 
here (subcortical brain structure: 20 tests; cortical thickness: 26 tests). 
 Secondary analyses examined whether lifetime maternal depression or current maternal 
depressive symptoms are correlated with brain structure or depressive symptoms in children and 
further whether child depressive symptoms were correlated with brain structure. For each of 
these outcomes, the same covariates were used with the exception that any antidepressant 
exposure (before or after maternal knowledge of pregnancy) was added as a covariate to the 
maternal depression analyses. Multiple testing was adjusted for using FDRBH (maternal 
depression and child brain structure each had the following number of tests: maternal depression: 







Chapter 3: Results 
3.1 Prenatal SSRI exposure and child depression outcomes 
Prenatal SSRI exposure was associated with increased depressive symptoms among children 
(b=0.95, p = 0.01; Figure 1; Table 2). Post hoc analyses revealed that prenatal SSRI exposure 
before, but not after, maternal knowledge of pregnancy was associated with increased depressive 
symptoms among children (before: b=1.101, p=0.0093, pFDR = 0.0186; after: b=0.35, p = 0.42, 
pFDR = 0.42).  
Figure 1. Mean current depressive symptoms in children exposed and unexposed prenatally to 
SSRIs. 
3.2 Prenatal SSRI exposure and child brain outcomes 
Prenatal SSRI exposure (i.e., before or after maternal knowledge of pregnancy, n=299 exposed, 
n=9,717 unexposed) was not associated with any brain structure outcome following correction 
for multiple testing (all pfdr >0.12; Tables 3-13). The following nominally significant 
































volumes: left caudate (b=-71.7; p=0.017), right hippocampus (b= -49.8; p=0.026), and left 
amygdala (b= -23.7, p=0.045). No associations between cortical thickness and prenatal SSRI 
exposure reached nominal levels of significance (all pfdr >0.90, p>0.19). Subsequent post-hoc 
analyses conducted independent for exposure before maternal knowledge of pregnancy (n=274 
exposed, 9,949 unexposed) and after maternal knowledge of pregnancy (n=212 exposed, 
n=10,155 unexposed) revealed no significant associations with subcortical volumes or cortical 
thickness after adjusting for multiple comparisons (all pfdr >0.13). The following nominally 
significant associations were observed: prenatal SSRI exposure before and after maternal 
knowledge of pregnancy was nominally associated with reduced left amygdala volume (before: 
b= -26.6, p=0.032; after: b= -38.7, p=0.005) and SSRI exposure before maternal knowledge of 
pregnancy was associated with reduced right hippocampus (b= -57.2, p=0.014) and bilateral 
caudate volumes (left: b= -81.1, p=0.0099; right: b= -66.8, p=0.035). 
3.3 Secondary Analyses 
3.3.1 Maternal depression and child depression and brain structure  
Lifetime presence of maternal depression and recent depressive symptoms (i.e., prior 6 months) 
were associated with increased child depressive symptoms (lifetime: b=2.15, t(df)=13.49(6,825), 





However, there was no evidence that lifetime or recent maternal depression was associated with 
child brain structure (all pfdr >0.29). The only nominally significant association to emerge from 
these analyses was that maternal lifetime depression was associated with decreased volume of 
the right putamen among children (b=-31.5, p=0.030). There were no nominally significant 
associations between recent maternal depressive symptoms and child brain structure (all ps 
>0.21). 
Figure 2. Mean current depressive symptoms in children with a maternal lifetime history of self-
reported depression versus children whose mothers were not reported to have a lifetime history 
of depression. 
 
3.3.2 Associations between child brain structure and depressive symptoms 
































Chapter 4: Discussion 
 
The present study examined whether prenatal SSRI exposure is associated with child depression 
and brain structure (i.e., subcortical volume and cortical thickness). Two primary findings 
emerged. First, consistent with evidence from non-human animal models (Ansorge, Morelli, & 
Gingrich, 2008; Ansorge, Zhou, Lira, Hen, & Gingrich, 2004) and a limited human literature 
(Hanley et al., 2015; Hermansen et al., 2016; Lupattelli et al., 2018), but see also (Grzeskowiak 
et al., 2016; Misri et al., 2006; Nulman et al., 2012, 2015, 1997), we found that prenatal exposure 
to SSRIs is associated with increased child depression risk, even after accounting for maternal 
lifetime depression history. Second, prenatal SSRI exposure was not associated with individual 
differences in subcortical volumes or cortical thickness. Further, child brain structure was not 
related to child depressive symptoms. Collectively, these data suggest SSRI exposure may 
independently contribute to depression risk among children but not individual variability in gray 
matter brain structure, at least as measured by MRI. While depression during pregnancy is 
associated with a host of negative outcomes (e.g., cardiac malformations, poor neonatal 
adaptation; Fitton et al., 2019), these data suggest that SSRI use during pregnancy may also be 
associated with negative outcomes (e.g. depression risk to offspring). 
 Prior research on prenatal SSRI exposure and depression risk has produced equivocal 
results. One interesting theme to note in the prior literature is that the studies that have assessed 
children at later ages observed a positive association between prenatal SSRI exposure and 





findings have been conducted in younger children (e.g., <age 5; (Misri et al., 2006; Nulman et 
al., 1997); but see also: (Grzeskowiak et al., 2016; Nulman et al., 2012, 2015)). It is possible that 
null associations reported in the literature could be partially attributable to younger aged 
samples. This is consistent with non-human animal work suggesting that rodents exposed to 
SSRIs during the equivalence of the third trimester do not display abnormal emotional behavior 
during puphood but do display depressive-like behavior as adults (Ansorge et al., 2004). Thus, 
the positive results we obtained among children who were on average 10 years old may be 
partially attributable to children entering middle childhood, when depressive symptoms begin to 
be more commonly expressed. However, prior studies reporting that prenatal SSRI exposure is 
associated with depressive-like phenotypes in children as young 18 months (Brandlistuen et al., 
2015) suggest that effects may be present earlier and that age alone cannot account for discrepant 
results in the literature. 
  It has long been speculated that SSRI exposure may influence brain structure 
development to increase risk for depression. Indeed, evidence from non-human animal models 
has shown that pregestational stress and prenatal stress, which are associated with depressive risk 
in offspring (Schmidt et al., 2018),  increase serotonin signaling (Huang et al., 2012). 
Additionally, prenatal SSRIs decrease S100B, which mediates the positive outgrowth and 
survival of neurons, in human neonates at birth (Pawluski, Galea, Brain, Papsdorf, & Oberlander, 
2009). As such, it is plausible that prenatal SSRI exposure may reduce neuronal survival and 
outgrowth through S100B. In contrast to these potential mechanisms, we find no evidence that 
prenatal SSRIs are associated with variability in child gray matter-related brain structure in 
specific ROIs at age 10. Together with evidence that variability in these brain structures were not 





be associated with depression via other mechanisms (e.g., structural connectivity, brain function, 
or finer grained brain structure). 
Lastly, maternal depression history was associated with increased depressive symptoms 
among children. However, we found no significant associations between maternal history of 
depression and childhood brain metrics after correcting for multiple testing. Consistent with a 
prior report using this dataset, we do find nominal evidence that maternal history of depression is 
associated with reduced right putamen volume among kids (Pagliaccio, Alqueza, Marsh, & 
Auerbach, 2019). However, this nominally significant association in our sample would not 
survive correction for multiple testing in our study. It is possible that brain structure may be 
predictive of depressive symptoms that develop later in adolescence and that early onset 
depressive symptoms are less tied to brain structure. 
4.1 Limitations and Future Directions 
Several limitations regarding the current study are important to note. First, we do not have 
information on maternal depression during pregnancy. While observed relationships with 
prenatal SSRI exposure were independent of maternal lifetime depression history, we cannot 
exclude the possibility that depression during pregnancy specifically may be responsible for 
these. Relatedly, it is possible that prenatal SSRI exposure may be a proxy for more severe 
maternal depression.  To confront these issues, after defending my master’s thesis, I will 
examine whether these associations are present when considering child polygenic risk for 
depression. Nonetheless, we will be unable to fully disarticulate maternal depression during 





Second, the analyzed dataset contained limited data on the timing of antidepressant 
exposure. While it was commendable to distinguish between exposure before or after knowledge 
of pregnancy given the thousands of other data points collected in the ABCD study, which was 
not designed to study prenatal exposure, the average point at which mothers knew they were 
pregnant in the sample was 6 weeks. Therefore, we cannot investigate differential effects of 
exposure with greater precision. Indeed, some evidence suggests that only SSRI exposure during 
late pregnancy (i.e., >29 weeks gestation) is associated with depression-related behavior among 
5 year olds (Lupattelli et al., 2018). It is possible that prenatal SSRI exposure is only associated 
with child brain structure at precise exposure times. Third, the sample size of children exposed to 
SSRIs (n=299), while larger than most previous studies, was still small, especially given the 
variability in exposure timing and different types of SSRIs taken.  
Fourth, we evaluated a priori brain regions based upon previous observations with 
depression. Given mounting evidence that clinical neuroscience may be plagued by false 
positives emerging from publication bias and underpowered heterogeneous patient samples, it is 
possible that priors from prior literature are misguiding. Before submitting this manuscript for 
publication, I will examine every brain region with correction for multiple testing. Further, it is 
possible that SSRIs might not impact gray matter metrics but may impact structural connectivity. 
Hence, after completing my master’s thesis, I will examine DTI-derived brain metrics. 
 Finally, our brain and depression metrics were derived from one session when children 
were on average 10 years of age. It is possible that SSRI exposure is associated with brain 
structure during earlier development and/or brain structure trajectories and that such associations 
may partially account for its association with depression. As the ABCD study will follow 





the opportunity for longitudinal analyses as children enter the period of developmental risk for 
depression. This will allow us to examine the effects of prenatal SSRI exposure on brain 
structure throughout adolescence, a critical period for brain development and psychopathology 
risk.  
4.2 Conclusions 
In a study of 11,076 children with structural MRI data from the ABCD dataset, we find evidence 
that prenatal SSRI exposure is associated with increased depression risk during middle childhood 
that is independent of lifetime maternal depression. There was no evidence that child MRI-
derived gray matter volume metrics (i.e. gray matter volume and cortical thickness across the 
whole brain and depression ROIs) may represent a mechanism underlying this association. 
Additional analyses will examine other imaging-derived metrics and whether observed 
associations between prenatal SSRI exposure and childhood depression remain when accounting 
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Age in years (11,076) 9.92 ± 0.62 9.94 ± 0.64 9.93 ± 0.63 9.94 ± 0.64 9.92 ± 0.62 
Gender, female (11,071) 4,648 (47.8%) 125 (45.6%) 87 (41.0%) 133 (44.5%) 5300 (47.9%) 
Birthweight in oz. (10,585) 112.62 ± 23.25 106.38 ± 25.57 105.47 ± 25.43 106.77 ± 25.21 112.16 ± 23.44 
Race/Ethnicity (11,076)  
White  7,237 (74.5%) 265 (96.7%) 208 (98.1%) 288 (96.3%) 8285 (74.8%) 
Black  2,037 (21.0%) 17 (6.2%) 13 (6.1%) 18 (6.0%) 2300 (20.8%) 
Asian 571 (5.9%) 5 (1.8%) 6 (2.8%) 7 (2.3%) 678 (6.1%) 
Pacific Islander 61 (0.6%) 0 (0%) 0 (0%) 0 (0%) 67 (0.6%) 
Native American 304 (3.1%) 12 (4.4%) 8 (3.8%) 12 (4.0%) 369 (3.3%) 
Hispanic 2,071 (21.3%) 23 (8.4%) 15 (7.1%) 26 (8.7%) 2254 (20.5%) 
Other 658 (6.8%) 10 (3.7%) 6 (2.8%) 11 (3.7%) 731 (6.6%) 
Pregnancy and Family Variables 
Planned Pregnancy (10,830) 5,971 (61.5%) 181 (66.1%) 149 (70.3%) 199 (66.6%) 6,634 (59.9%) 
Prenatal Vitamin Use (10,627) 9,121 (93.9%) 260 (94.9%) 202 (95.3%) 285 (95.3%) 10,140 (91.6%) 
Week Learned Pregnancy (9,794) 6.91 ± 6.76 7.30 ± 7.53 6.95 ± 7.24 7.09 ± 7.26 6.93 ± 6.80 
Maternal Education: Years (10,326) 16.57 ± 2.78 17.57± 1.79 17.52 ± 1.86 17.57 ± 1.79 16.62 ± 2.75 
Household Income (10,146)  
 Less than $50k 2,658 (27.4%) 44 (16.1%) 31 (14.62%) 48 (16.1 %) 2,966 (26.8%) 
          $50k-$99,999k 2,503 (25.8%) 88 (32.1%) 58 (27.4%) 94 (31.4%) 2,894 (26.1%) 
          $100k or more 3,733 (38.4%) 128 (46.7%) 109 (51.4%) 141 (47.2%) 4286 (38.7%) 
Maternal History of Dep (10,516) 1,980 (20.4%) 178 (65.0%) 130 (61.3%) 194 (64.9%) 2473 (22.3%) 
Maternal Recent Dep Sxs (9,377) 53.73 ± 5.70 59.11± 7.73 58.73 ± 7.56 58.92 ± 7.64 54.01 ± 5.94 
Prenatal Substance Exposure Before Knowing of Pregnancy  
SSRI (10,223) 0 (0%) 274 (100%) 187 (88.21%) 274 (91.64%) 274 (2.47%) 
Alcohol (10,429) 2,280 (23.5%) 97 (35.4%) 69 (32.6%) 103 (34.5%) 2675 (24.2%) 
Tobacco (10,813) 1,221 (12.6%) 36 (13.1%) 20 (9.4%) 39 (13.0%) 1478 (13.3%) 
Cannabis (10,755) 492 (5.1%) 17 (6.2%) 8 (3.8%) 19 (6.4%) 622 (5.6%) 
Prenatal Substance Exposure After Knowing of Pregnancy  
SSRI (10,367) 0 (0%) 187 (68.3%) 212 (100%) 212 (70.9%) 212 (1.9%) 
Alcohol (10,798) 216 (2.2%) 8 (2.9%) 8 (3.8%) 8 (2.7%) 299 (2.7%) 
Tobacco (10,828) 424 (4.4%) 11 (4.0%) 6 (2.8%) 11 (3.7%) 556 (5.0%) 
Cannabis (10,813)  155 (1.6%) 6 (2.2%) 3 (1.4%) 7 (2.3%) 218 (2.0%) 
Child Primary Outcomes of Interest 
Child Depression 
CBCL DSM-5 Depressive Sxs (11,068) 53.40 ± 5.56 55.77 ± 7.24 55.33 ± 7.22 55.78 ± 7.37 53.59 ± 5.73 
Lifetime Depression Diagnosis (10,990) 485 (5.0%) 15 (5.8%) 9 (4.3%) 17 (5.7%) 550 (5.0%) 
MDD Current 56 (0.6%) 0 (0%) 0 (0%) 0 (0%) 64 (0.6%) 
MDD Partial Remission 25 (0.3%) 0 (0%) 0 (0%) 0 (0%) 25 (0.2%) 
MDD Past 202 (2.1%) 10 (3.7%) 7 (3.3%) 11 (3.7%) 233 (2.1%) 
PDD Current 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
PDD Partial Remission 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
PDD Past 5 (0.1%) 1 (0.4%) 0 (0%) 1 (0.3%) 7 (0.06%) 
NOS Depression Current 22 (0.2%) 0 (0%) 0 (0%) 0 (0%) 24 (0.2%) 
NOS Depression Past 214 (2.2%) 5 (1.8%) 2 (0.9%) 6 (2.0%) 241 (2.2%) 





Notes: Dep = Depression; Sxs = Symptoms; SSRI = Selective Serotonin Reuptake Inhibitor; CBCL = Child Behavior Checklist; 
DSM-5 = Diagnostic and Statistical Manual of Mental Disorders, 5th edition; MDD = Major Depressive Disorder; PDD = 
Persistent Depressive Disorder; NOS = Not Otherwise Specified (i.e. Unspecified); ICV = intracranial volume; L = left; R = 
right; OFC = orbitofrontal cortex; ACC = anterior cingulate cortex;  * Some participants with acceptable MRI data did not have 
data for prenatal SSRI exposure. Therefore, the column totals do not add up to 11,076. Values are either N(%) or mean ± standard 
deviation. Units for subcortical volumes are mm3 and for cortical thickness are mm.  
Total Cortical Thickness 2.78 ± 0.10 2.80 ± 0.10 2.80 ± 0.10 2.80 ± 0.10 2.78 ± 0.10 










Subcortical Volumes (n=11,070) 
Amygdala (L) 1573.02 ± 
229.54 






Amygdala (R) 1615.92 ± 
228.43 






Caudate (L) 4011.80 ± 
527.14 






Caudate (R) 4162.21 ± 
535.77 






Hippocampus (L) 4042.94 ± 
434.98 






Hippocampus (R) 4094.74 ± 
429.79 






Nucleus Accumbens (L) 568.26 ± 115.15 571.97 ± 117.82 580.16 ± 112.81 570.95 ± 114.85 567.55 ± 115.13 
Nucleus Accumbens (R) 617.66 ± 99.26 615.62 ± 96.18 621.67 ± 91.13 613.47 ± 94.49 616.46 ± 99.19 
Putamen (L) 5955.33 ± 
711.01 






Putamen (R) 5790.91 ± 
629.76 






Cortical Thickness (n=11,070) 
Caudal Middle Frontal Cortex (L) 2.88 ± 0.15 2.88 ± 0.15 2.88 ± 0.14 2.88 ± 0.14 2.88 ± 0.15 
Caudal Middle Frontal Cortex (R) 2.85 ± 0.15 2.84 ± 0.15 2.85 ± 0.15 2.84 ± 0.15 2.85 ± 0.15 
Lateral OFC (L) 2.99 ± 0.15 3.00 ± 0.14 3.00 ± 0.14 3.00 ± 0.14 2.99 ± 0.15 
Lateral OFC (R) 2.96 ± 0.16 2.98 ± 0.15 2.98 ± 0.15 2.98 ± 0.15 2.96 ± 0.16 
Medial OFC (L) 2.73 ± 0.17 2.74 ± 0.17 2.74 ± 0.17 2.74 ± 0.17 2.73 ± 0.17 
Medial OFC (R) 2.75 ± 0.18 2.77 ± 0.18 2.77 ± 0.17 2.77 ± 0.18 2.75 ± 0.18 
Rostral ACC (L) 3.16 ± 0.21 3.18 ± 0.21 3.16 ± 0.20 3.18 ± 0.20 3.17 ± 0.21 
Rostral ACC (R) 3.06 ± 0.22 3.07 ± 0.20 3.05 ± 0.20 3.06 ± 0.21 3.06 ± 0.22 
Rostral Middle Frontal Cortex (L) 2.73 ± 0.15 2.75 ± 0.15 2.75 ± 0.15 2.75 ± 0.15 2.73 ± 0.15 
Rostral Middle Frontal Cortex (R) 2.69 ± 0.15 2.70 ± 0.15 2.70 ± 0.15 2.70 ± 0.15 2.69 ± 0.15 
Superior Frontal Cortex (L) 3.14 ± 0.15 3.14 ± 0.15 3.15 ± 0.15 3.15 ± 0.15 3.14 ± 0.15 






Table 2. Prenatal SSRI Exposure and Child Depressive Symptoms: Full Regression Results 
N= 7,403 Child Depressive Symptoms 
Variable b  p 
Variable of Interest 
Prenatal SSRI Exposure 0.9516 0.010585 
Pregnancy and Family Variables 
Planned Pregnancy  -0.2559 0.095073 
Prenatal Vitamin Use  -0.3.532 0.301420 
Week Learned Pregnancy  6.802e-03 0.495693 
Maternal Education: Years  -2.249e-04 0.994555 
Household Income 
          $50k-$99,999 -0.8883 8.74e-06 
          $100k or more -1.447 7.40e-11 
Prenatal Exposure Before Maternal Knowledge 
Alcohol 0.2563 0.119135 
Tobacco  0.5309 0.037145 
Cannabis  0.04981 0.889545 
Prenatal Exposure After Maternal Knowledge 
Alcohol  0.9060 0.046550 
Tobacco  -0.07660 0.850914 
Cannabis 0.5319 0.415376 
Maternal History of Depression 2.185 < 2e-16 
Child Variables 
Age 0.01940 0.022847 
Sex 0.7658 3.23e-09 
Birthweight -2.975e-03 0.382417 
Race and Ethnicity 
White  0.9415 0.000129 
Black -0.2731 0.279889 
Asian 0.2027 0.501435 
Pacific Islander -1.093 0.203159 
Native American 0.7146 0.069327 
Other Race 0.8798 0.008690 
























N = 7,399 Amygdala 
 Left Right 
Variable b  p b  p 
Variable of Interest 
Prenatal SSRI Exposure -23.71 0.0451 -17.91 0.1263 
Pregnancy and Family Variables 
Planned Pregnancy 2.387 0.6250 -6.832 0.1580 
Prenatal Vitamin Use -5.213 0.6316 27.45 0.0108 
Week Learned Pregnancy  0.3415 0.2825 0.4318 0.1702 
Maternal Education: Years  2.006 0.0570 1.513 0.1470 
Household Income 
          $50k-$99,999 3.692 0.5618 5.162 0.4125 
          $100k or more 5.468 0.4404 9.182 0.1908 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  3.862 0.4612 -0.9170 0.8598 
Tobacco  -8.089 0.3185 -13.79 0.0859 
Cannabis  11.56 0.3110 18.20 0.1073 
Prenatal Exposure After Maternal Knowledge 
Alcohol 1.358 0.9254 19.67 0.1709 
Tobacco -5.283 0.6837 -15.51 0.2272 
Cannabis  1.120 0.9570 10.38 0.6142 
Maternal History of Depression -6.672 0.1980 -1.271 0.8043 
Child Variables 
Age 0.5382 0.0486 0.03871 0.8864 
Sex 54.99 < 2e-16 49.60 < 2e-16 
Birthweight -0.06115 0.5788 -0.1028 0.3465 
Race and Ethnicity 
White  1.487 0.8500 -1.479 0.8494 
Black -46.15 1.25e-08 -34.44 1.77e-05 
Asian -3.008 0.7559 -7.670 0.4234 
Pacific Islander -36.57 0.1803 -32.19 0.2332 
Native American 23.84 0.0585 28.66 0.0216 
Other Race -2.654 0.8039 -12.61 0.2338 

























 Left Right 
Variable b p b  p 
Variable of Interest 
Prenatal SSRI Exposure -71.74 0.01727 -53.18 0.080238 
Pregnancy and Family Variables 
Planned Pregnancy  -7.593 0.53552 13.01 0.294582 
Prenatal Vitamin Use  -25.24 0.35738 -26.18 0.345255 
Week Learned Pregnancy 0.5472 0.49378 0.4155 0.607730 
Maternal Education: Years  7.939 0.00310 9.276 0.000615 
Household Income 
          $50k-$99,999 29.45 0.06954 13.92 0.394782 
          $100k or more 3.964 0.82622 -0.8282 0.963733 
Prenatal Exposure Before Maternal Knowledge 
Alcohol -15.88 0.23178 -14.59 0.276702 
Tobacco  -1.773 0.93121 6.232 0.763901 
Cannabis -9.233 0.74850 -16.95 0.560488 
Prenatal Exposure After Maternal Knowledge 
Alcohol  -24.72 0.49848 -36.70 0.320498 
Tobacco -27.67 0.39892 -41.81 0.207344 
Cannabis 55.82 0.28592 55.20 0.296953 
Maternal History of Depression -1.210 0.92662 -3.570 0.787919 
Child Variables 
Age -1.959 0.00316 -2.313 0.000653 
Sex -67.08 7.58e-09 -78.17 3.49e-11 
Birthweight 0.6194 0.02495 0.5443 0.051886 
Race and Ethnicity 
White  42.68 0.03179 41.63 0.038328 
Black 13.13 0.52411 33.27 0.109816 
Asian -41.35 0.09207 -47.31 0.056427 
Pacific Islander 75.95 0.27723 -16.10 0.387386 
Native American -14.27 0.65500 60.92 0.617851 
Other Race -6.837 0.79910 1.479 0.956642 




























N= 7,399 Hippocampus 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure -22.30 0.343625 -49.77 0.025629 
Pregnancy and Family Variables 
Planned Pregnancy  -4.814 0.618316 6.297 0.490645 
Prenatal Vitamin Use 32.11 0.136422 39.57 0.052385 
Week Learned Pregnancy  -0.03025 0.961666 0.6449 0.278737 
Maternal Education: Years 3.551 0.089096 2.195 0.267138 
Household Income 
          $50k-$99,999 25.13 0.046679 25.01 0.036633 
          $100k or more 34.31 0.014548 30.14 0.023436 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  -9.049 0.383587 6.422 0.513596 
Tobacco -10.81 0.501876 -3.632 0.811554 
Cannabis  37.00 0.102022 40.25 0.060091 
Prenatal Exposure After Maternal Knowledge 
Alcohol -0.3405 0.990540 6.205 0.819276 
Tobacco -4.536 0.860156 -41.23 0.090629 
Cannabis  -15.78 0.701483 -40.28 0.300931 
Maternal History of Depression -9.357 0.363087 -7.336 0.451237 
Child Variables 
Age 0.6833 0.200343 0.5701 0.256823 
Sex 32.21 0.000434 29.52 0.000643 
Birthweight -0.1739 0.424059 -0.04951 0.809791 
Race and Ethnicity 
White  9.935 0.523282 10.21 0.488152 
Black -70.30 1.13e-05 -79.86 1.41e-07 
Asian -7.947 0.676822 14.46 0.423113 
Pacific Islander -17.99 0.741190 -75.20 0.145266 
Native American -17.34 0.485203 -23.28 0.322576 
Other Race -13.01 0.537869 -4.190 0.833865 





Table 6. Prenatal SSRI Exposure and Child Nucleus Accumbens Volume: Full Regression 
Results 
N=7,399 Nucleus Accumbens 
 Left Right 
Variable b p b  p 
Variable of Interest 
Prenatal SSRI Exposure -0.1038 0.98672 -8.422 0.12814 
Pregnancy and Family Variables 
Planned Pregnancy -1.992 0.44030 4.771 0.03662 
Prenatal Vitamin Use -0.8652 0.88021 2.172 0.66903 
Week Learned Pregnancy  -0.1623 0.33355 -0.08096 0.58568 
Maternal Education: Years -0.2037 0.71396 -0.1392 0.77768 
Household Income 
          $50k-$99,999 2.783 0.40682 4.339 0.14494 
          $100k or more 0.6966 0.85217 3.805 0.25120 
Prenatal Exposure Before Maternal Knowledge 
Alcohol -1.565 0.57149 -2.461 0.31540 
Tobacco -5.142 0.22943 -6.077 0.10903 
Cannabis -3.905 0.51703 5.672 0.28766 
Prenatal Exposure After Maternal Knowledge 
Alcohol -4.433 0.56288 3.697 0.58532 
Tobacco -3.768 0.58180 -3.015 0.61904 
Cannabis 0.5941 0.95684 -5.432 0.57589 
Maternal History of Depression -0.4744 0.86225 -1.655 0.49473 
Child Variables 
Age -0.4686 0.00123 -0.7657 1.87e-09 
Sex 1.108 0.65327 3.603 0.09803 
Birthweight 0.2982 3.12e-07 0.2961 9.25e-09 
Race and Ethnicity 
White  -7.802 0.06020 -4.651 0.20583 
Black -6.195 0.14699 0.3097 0.93485 
Asian -5.941 0.24475 -7.039 0.11987 
Pacific Islander -24.06 0.09382 -24.16 0.05869 
Native American 0.4475 0.94635 -3.867 0.51178 
Other Race -2.284 0.68610 -2.672 0.59278 























N = 7,399 Putamen 
 Left Right 
Variable b p b  p 
Variable of Interest 
Prenatal SSRI Exposure -18.17 0.64984 21.17 0.5396 
Pregnancy and Family Variables 
Planned Pregnancy  24.97 0.12770 23.40 0.0962 
Prenatal Vitamin Use  33.13 0.36525 36.59 0.2445 
Week Learned Pregnancy  0.3896 0.71532 -0.1688 0.8540 
Maternal Education: Years  -1.282 0.71878 -1.933 0.5294 
Household Income 
          $50k-$99,999 46.50 0.03070 25.86 0.1639 
          $100k or more 33.16 0.16604 20.80 0.3144 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  -5.788 0.74318 -5.880 0.6992 
Tobacco 32.34 0.23703 39.70 0.0917 
Cannabis 12.49 0.74499 2.871 0.9307 
Prenatal Exposure After Maternal Knowledge 
Alcohol 88.89 0.06813 53.06 0.2052 
Tobacco 10.90 0.80316 -8.576 0.8196 
Cannabis 46.80 0.50282 90.02 0.1335 
Maternal History of Depression -16.26 0.35234 -30.67 0.0416 
Child Variables 
Age -2.502 0.00547 -3.464 6.02e-06 
Sex 120.8 9.14e-15 143.4 < 2e-16 
Birthweight -0.1993 0.58955 -0.2123 0.5030 
Race and Ethnicity 
White  26.83 0.31074 17.37 0.4460 
Black -44.09 0.10653 -71.69 0.0024 
Asian 95.02 0.00352 114.5 4.76e-05 
Pacific Islander 26.55 0.77464 -22.94 0.7744 
Native American -75.78 0.07399 -39.52 0.2802 
Other Race 12.44 0.72873 70.56 0.0221 





Table 8. Prenatal SSRI Exposure and Child Caudal Middle Frontal Gyrus Cortical 

















N = 7,399 Caudal Middle Frontal Gyrus 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure 5.630e-03 0.555016 -2.341e-03 0.80924 
Pregnancy and Family Variables 
Planned Pregnancy  -6.178e-03 0.117393 -6.396e-03 0.11087 
Prenatal Vitamin Use  0.01214 0.166606 2.396e-04 0.97857 
Week Learned Pregnancy  1.212e-04 0.636611 4.569e-04 0.07991 
Maternal Education: Years  2.671e-04 0.753154 -4.120e-04 0.63328 
Household Income 
          $50k-$99,999 7.840e-03 0.126384 0.01374 0.00844 
          $100k or more 4.794e-03 0.401506 0.01158 0.04624 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  -5.571e-03 0.187714 -0.01127 0.00877 
Tobacco -2.952e-03 0.651823 -5.374e-03 0.41900 
Cannabis -8.221e-03 0.372199 -5.641e-04 0.95198 
Prenatal Exposure After Maternal Knowledge 
Alcohol 0.01373 0.240863 0.02910 0.01455 
Tobacco -5.464e-04 0.958343 0.01090 0.30528 
Cannabis  9.973e-03 0.552278 -0.01690 0.32196 
Family History of Depression 3.807e-04 0.927445 -3.839e-03 0.36635 
Child Variables 
Age -4.815e-04 0.029596 -4.245e-04 0.05942 
Sex -0.02795 1.34e-13 -0.03661 < 2e-16 
Birthweight 4.438e-05 0.617994 1.927e-04 0.03327 
Race and Ethnicity 
White  8.974e-03 0.157286 6.825e-03 0.29007 
Black 0.01159 0.075888 8.743e-03 0.18773 
Asian -0.01383 0.076355 -0.01265 0.11078 
Pacific Islander -9.884e-03 0.652736 -0.04433 0.04710 
Native American -5.694e-03 0.575275 -0.01781 0.08476 
Other Race -8.285e-04 0.923555 -0.01094 0.21261 





Table 9. Prenatal SSRI Exposure and Child Rostral Middle Frontal Gyrus Cortical 


















N= 7,399 Rostral Middle Frontal Gyrus 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure 2.187e-03 0.806278 6.736e-03 0.45498 
Pregnancy and Family Variables 
Planned Pregnancy  -3.986e-03 0.278974 -2.666e-03 0.47337 
Prenatal Vitamin Use  5.214e-03 0.524532 2.256e-03 0.78520 
Week Learned Pregnancy  2.370e-04 0.322413 1.767e-04 0.46525 
Maternal Education: Years  1.468e-03 0.064512 1.515e-03 0.05926 
Household Income 
          $50k-$99,999 4.465e-03 0.351760 4.130e-03 0.39434 
          $100k or more 3.518e-03 0.510191 1.239e-03 0.81862 
Prenatal Exposure Before Maternal Knowledge 
Alcohol -1.738e-03 0.659970 -4.340e-03 0.27698 
Tobacco 5.954e-04 0.922385 -6.142e-03 0.31997 
Cannabis -1.144e-03 0.894137 -1.085e-03 0.90065 
Prenatal Exposure After Maternal Knowledge 
Alcohol 0.02343 0.032073 0.01955 0.07655 
Tobacco -7.365e-03 0.451020 7.507e-03 0.44721 
Cannabis 0.01093 0.485211 -0.01105 0.48499 
Maternal History of Depression 2.424e-03 0.534838 -8.922e-04 0.82120 
Child Variables 
Age -1.911e-03 < 2e-16 -1.749e-03 < 2e-16 
Sex 7.312e-03 0.037546 6.418e-03 0.07053 
Birthweight -3.822e-05 0.645342 -6.209e-05 0.45915 
Race and Ethnicity 
White  9.454e-03 0.110683 0.01077 0.07225 
Black -0.01758 0.004001  -0.01930 0.00178 
Asian -4.200e-03 0.564767 -3.198e-03 0.66439 
Pacific Islander -8.668e-03 0.673372 -0.02938 0.15805 
Native American 4.719e-03 0.619353 -2.347e-03 0.80686 
Other Race 2.230e-03 0.782009 4.283e-03 0.59875 
























N= 7,399 Lateral OFC 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure -0.01284 0.19386 -8.434e-03 0.400181 
Pregnancy and Family Variables 
Planned Pregnancy  -3.163e-03 0.43943 1.368e-03 0.742450 
Prenatal Vitamin Use  5.624e-03 0.53654 0.01377 0.136727 
Week Learned Pregnancy  -1.251e-04 0.63801 9.480e-05 0.726015 
Maternal Education: Years  1.089e-03 0.21594 1.498e-03 0.093554 
Household Income 
          $50k-$99,999 0.01113 0.03622 0.01090 0.043293 
          $100k or more 0.01299 0.02823 0.01232 0.040300 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  1.768e-03 0.68654 -5.060e-04 0.909515 
Tobacco  -2.611e-03 0.70014 -6.471e-03 0.347355 
Cannabis  -3.889e-03 0.68383 -2.442e-03 0.801518 
Prenatal Exposure After Maternal Knowledge 
Alcohol  0.01287 0.28923 -5.248e-03 0.671115 
Tobacco -3.398e-03 0.75393 3.041e-03 0.782406 
Cannabis 0.01560 0.36987 0.01875 0.289694 
Maternal History of Depression 4.885e-03 0.25956 2.479e-03 0.573243 
Child Variables 
Age -2.481e-03 < 2e-16 -2.344e-03 < 2e-16 
Sex 0.01043 0.00758 6.594e-03 0.097753 
Birthweight -2.827e-04 0.00219 -2.558e-04 0.006467 
Race and Ethnicity 
White  0.02676 4.75e-05 0.02460 0.000234 
Black -0.01607 0.01746 -0.02358 0.000593 
Asian -0.01156 0.15250 -7.414e-03 0.366620 
Pacific Islander -0.03285 0.14869 -0.03519 0.126003 
Native American 9.702e-04 0.92655 2.414e-03 0.821408 
Other Race 0.02235 0.01257 0.02253 0.013430 
























N= 7,399 Medial OFC 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure 5.630e-03 0.555016 7.235e-03 0.51023 
Pregnancy and Family Variables 
Planned Pregnancy  -6.178e-03 0.117393 -1.567e-03 0.73098 
Prenatal Vitamin Use  0.01214 0.166606 0.02779 0.00609 
Week Learned Pregnancy  1.212e-04 0.636611 -2.032e-04 0.49263 
Maternal Education: Years  2.671e-04 0.753154 1.610e-03 0.10016 
Household Income 
          $50k-$99,999 7.840e-03 0.126384 8.607e-03 0.14520 
          $100k or more 4.794e-03 0.401506 6.227e-03 0.34432 
Prenatal Exposure Before Maternal Knowledge 
Alcohol -5.571e-03 0.187714 -1.216e-03 0.80314 
Tobacco -2.952e-03 0.651823 -6.625e-03 0.37975 
Cannabis -8.221e-03 0.372199 5.161e-03 0.62742 
Prenatal Exposure After Maternal Knowledge 
Alcohol  0.01373 0.240863 0.01730 0.20093 
Tobacco  -5.464e-04 0.958343 0.01553 0.19778 
Cannabis  9.973e-03 0.552278 9.261e-03 0.63267 
Maternal History of Depression 3.807e-04 0.927445 1.099e-03 0.81972 
Child Variables 
Age -4.815e-04 0.029596 -2.745e-03 < 2e-16 
Sex -0.02795 1.34e-13 0.01393 0.00139 
Birthweight 4.438e-05 0.617994 -5.750e-04 2.29e-08 
Race and Ethnicity 
White  8.974e-03 0.157286 6.930e-03 0.34371 
Black 0.01159 0.075888 -0.01415 0.06004 
Asian -0.01383 0.076355 7.890e-03 0.38054 
Pacific Islander -9.884e-03 0.652736 -0.04675 0.06408 
Native American -5.694e-03 0.575275 0.01392 0.23498 
Other Race -8.285e-04 0.923555 -4.205e-03 0.67325 

























N=7,399 Rostral ACC 
 Left Right 
Variable b  p b p 
Variable of Interest 
Prenatal SSRI Exposure -0.01059 0.415030 -0.01051 0.4430 
Pregnancy and Family Variables 
Planned Pregnancy  -4.879e-03 0.366047 -4.573e-03 0.4210 
Prenatal Vitamin Use  8.845e-04 0.941215 2.865e-03 0.8206 
Week Learned Pregnancy  -2.173e-04 0.535559 9.998e-05 0.7866 
Maternal Education: Years  1.098e-03 0.343205 2.371e-03 0.0522 
Household Income 
          $50k-$99,999 2.033e-04 0.976782 -1.638e-03 0.8240 
          $100k or more -2.372e-03 0.760624  -9.679e-03 0.2385 
Prenatal Exposure Before Maternal Knowledge 
Alcohol  4.787e-03 0.406829 -1.166e-03 0.8480 
Tobacco -5.947e-03 0.505168 2.586e-03 0.7834 
Cannabis -0.01200 0.340421  -5.550e-03 0.6756 
Prenatal Exposure After Maternal Knowledge 
Alcohol 0.01780 0.266691 -5.370e-03 0.7502 
Tobacco 0.01472 0.302232 -0.01784 0.2358 
Cannabis 0.02989 0.192844 -0.03064 0.2049 
Maternal History of Depression 3.500e-03 0.539409 5.844e-03 0.3310 
Child Variables 
Age -2.712e-03 < 2e-16 -2.233e-03 3.41e-12 
Sex -0.01728 0.000824 1.312e-03 0.8091 
Birthweight -4.555e-04 0.000185 -2.267e-04 0.0770 
Race and Ethnicity 
White  0.02940 0.000694 0.01916 0.0359 
Black 0.01727 0.052186 -0.01142 0.2235 
Asian -0.02350 0.027376 -8.366e-03 0.4558 
Pacific Islander -0.01191 0.689074 -0.01262 0.6885 
Native American -1.706e-05 0.999018 0.01425 0.3295 
Other Race 0.01149 0.330942 0.02171 0.0809 





Table 13. Prenatal SSRI Exposure and Child Superior Frontal Gyrus Cortical Thickness: 



















N= 7,339 Superior Frontal Gyrus 
 Left Right 
Variable b p b p 
Variable of Interest 
Prenatal SSRI Exposure 1.125e-03 0.90382 3.764e-04 0.9677 
Pregnancy and Family Variables 
Planned Pregnancy  -3.411e-03 0.37343 -1.883e-04 0.9607 
Prenatal Vitamin Use  7.490e-03 0.38034 9.748e-03 0.2525 
Week Learned Pregnancy  1.312e-04 0.59888 1.216e-04 0.6251 
Maternal Education: Years  1.109e-03 0.18126 1.407e-03 0.0889 
Household Income  
          $50k-$99,999 7.712e-03 0.12374 8.156e-03 0.1025 
          $100k or more 5.971e-03 0.28459 5.149e-03 0.3547 
Prenatal Exposure Before Maternal Knowledge 
Alcohol -4.706e-03 0.25351 -2.615e-03 0.5246 
Tobacco -1.365e-03 0.83045 -4.920e-03 0.4390 
Cannabis 7.654e-04 0.93194 -6.838e-04 0.9390 
Prenatal Exposure After Maternal Knowledge 
Alcohol 0.02746 0.01583 0.02643 0.0199 
Tobacco -3.792e-03 0.70987 5.193e-03 0.6095 
Cannabis 3.274e-03 0.84092 -7.656e-03 0.6380 
Maternal History of Depression -2.175e-03 0.59358 4.187e-04 0.9179 
Child Variables 
Age -1.344e-03 2.81e-10 -1.192e-03 2.16e-08 
Sex -0.01507 3.73e-05 -0.01449 7.10e-05 
Birthweight -2.411e-04 0.00529 -1.576e-04 0.0678 
Race and Ethnicity 
White  9.487e-03 0.12474 6.436e-03 0.2964 
Black 5.012e-03 0.43180 -2.780e-03 0.6619 
Asian -0.01010 0.18433 -4.586e-03 0.5457 
Pacific Islander -0.01980 0.35778 -0.02760 0.1983 
Native American -4.375e-03 0.65890 -5.639e-03 0.5683 
Other Race 1.522e-03 0.85606 1.605e-03 0.8479 
Hispanic -0.01440 0.00835 -0.01126 0.0384 
